Clinical utility of glycated albumin and 1,5-anhydroglucitol in the screening and prediction of diabetes: A multi-center study

Figure 1 Receiver operating characteristic curve analyses of prediabetes and diabetes in the Obese Chinese Cohort. A: Prediabetes in the Obese Chinese Cohort (OCC); B: Diabetes in the OCC. GA: Glycated albumin; 1,5-AG: 1,5-anhydroglucitol; AUC: Area under the receiver operating characteristic curve.

Figure 2 Relative change in fasting plasma glucose, glycated hemoglobin, glycated albumin and 1,5-anhydroglucitol levels after bariatric surgery among morbidly-obese patients with diabetes. GA: Glycated albumin; 1,5-AG: 1,5-anhydroglucitol; FPG: Fasting plasma glucose; HbA1c: Glycated hemoglobin.

Figure 3 Receiver operating characteristic curve analyses of the different models. Clinical Model 1: Body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour glucose; Clinical Model 2: BMI, HbA1c, FPG, triglycerides; ‘B3A’ Model: BMI, HbA1c, glycated albumin, 1,5-anhydroglucitol.